June 30, 2023 07:08 AM EDT
People

Bellerophon Ther­a­peu­tics lets al­most all em­ploy­ees go, looks for deals in wake of PhI­II flop

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­its con­tin­ue at FDA, as more staff in drug of­fice fol­low fired col­leagues out the door

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

FDA ap­proves J&J's rare dis­ease drug that's ex­pect­ed to com­pete with ar­genx and UCB

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Re­gen­eron los­es bid to fend off DOJ fight over Eylea Medicare pay­ments

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times